Compositions for treating addiction
AssigneeCuremark, LLC
InventorsJoan M. Fallon, Matthew F. Heil
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for use in the treatment of the symptoms of an addiction is disclosed. The pharmaceutical composition contains, but is not limited to, digestive enzymes. The pharmaceutical composition may further contain a coating that surrounds a core of digestive enzymes in the form of coated particles. The pharmaceutical composition may also be encapsulated. The therapeutic agent may be manufactured by a variety of technologies.
Claims40
(canceled)
(canceled)
A method of reducing an elevated amount of ΔFos in a subject having an addiction, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises digestive enzymes, wherein ΔFos is elevated in the subject due to the addiction compared to a subject without the addiction.
A method of decreasing an amount or a length of dendritic spines in nerve cells of a subject having an addiction, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises digestive enzymes, thereby decreasing the amount or the length of the dendritic spines in nerve cells of the subject to an amount that is lower than prior to administration of the pharmaceutical composition.
6-9. (canceled)
11-13. (canceled)
(canceled)
17-20. (canceled)
22-29. (canceled)
(canceled)
(canceled)
(canceled)
39-45. (canceled)
50-53. (canceled)
55-59. (canceled)
62-94. (canceled)
A pharmaceutical composition for treatment of an addiction in a subject in need thereof, wherein the pharmaceutical composition comprises encapsulated, coated digestive enzyme particles, wherein the coated digestive enzyme particles comprise (i) a core that comprises digestive enzymes that comprise a protease, an amylase, and a lipase, and (ii) a coating.
96-119. (canceled)
Dependencies are inferred from the claim text.